Primecap Management CO Bei Gene, Ltd. Transaction History

Primecap Management CO

$132 Billion
Q1 2024

A detailed history of Primecap Management CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Primecap Management CO holds 5,001,839 shares of BGNE stock, worth $745 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares

5,001,839

Previous 4,988,639 0.26%

Holding current value

$745 Million

Previous $900 Million 13.06%

% of portfolio

0.59%

Previous 0.72%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$141.8 - $181.47 $1.87 Million - $2.4 Million	13,200 Added 0.26%	5,001,839 $782 Million
Q4 2023 Feb 09, 2024	SELL	$158.67 - $201.58 $3.19 Million - $4.05 Million	-20,100 Reduced 0.4%	4,988,639 $900 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $1.06 Million - $1.33 Million	-5,910 Reduced 0.12%	5,008,739 $901 Million
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $5.58 Million - $8.34 Million	-31,275 Reduced 0.62%	5,014,649 $894 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $480,631 - $612,135	-2,230 Reduced 0.04%	5,045,924 $1.09 Billion

Q4 2022 Feb 13, 2023	BUY	$125.51 - $229.3 $39.3 Million - $71.8 Million	313,175 Added 6.61%	5,048,154 $1.11 Billion
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $92.7 Million - $142 Million	703,530 Added 17.45%	4,734,979 $638 Million
Q2 2022 Aug 11, 2022	BUY	$121.11 - $216.05 $39.1 Million - $69.7 Million	322,645 Added 8.7%	4,031,449 $652 Million
Q1 2022 May 11, 2022	SELL	$146.52 - $269.56 $1.28 Million - $2.35 Million	-8,703 Reduced 0.23%	3,708,804 $699 Million
Q4 2021 Feb 11, 2022	SELL	$248.56 - $389.34 $23.3 Million - $36.5 Million	-93,840 Reduced 2.46%	3,717,507 $1.01 Billion
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $11.6 Million - $18.8 Million	-46,613 Reduced 1.21%	3,811,347 $1.38 Billion
Q2 2021 Aug 10, 2021	SELL	$292.75 - $367.01 $9.04 Million - $11.3 Million	-30,879 Reduced 0.79%	3,857,960 $1.32 Billion
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $136 Million - $200 Million	522,112 Added 15.51%	3,888,839 $1.35 Billion
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $1.23 Million - $1.76 Million	-5,560 Reduced 0.16%	3,366,727 $870 Million
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $306 Million - $463 Million	1,616,090 Added 92.02%	3,372,287 $966 Million
Q2 2020 Aug 13, 2020	BUY	$123.9 - $195.41 $6.96 Million - $11 Million	56,176 Added 3.3%	1,756,197 $331 Million
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $85.5 Million - $121 Million	701,444 Added 70.24%	1,700,021 $209 Million
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $1.78 Million - $3.2 Million	15,347 Added 1.56%	998,577 $166 Million
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $6.56 Million - $8.07 Million	54,391 Added 5.86%	983,230 $120 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $957,516 - $1.23 Million	8,400 Added 0.91%	928,839 $115 Million
Q1 2019 May 14, 2019	SELL	$122.82 - $151.83 $135,102 - $167,013	-1,100 Reduced 0.12%	920,439 $121 Million
Q4 2018 Feb 12, 2019	BUY	$107.01 - $175.15 $4.92 Million - $8.06 Million	46,000 Added 5.25%	921,539 $129 Million
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $2.78 Million - $3.45 Million	18,206 Added 2.12%	875,539 $151 Million
Q2 2018 Aug 13, 2018	SELL	$152.5 - $216.77 $25,315 - $35,983	-166 Reduced 0.02%	857,333 $132 Million
Q1 2018 May 14, 2018	BUY	$97.41 - $177.22 $53.6 Million - $97.6 Million	550,479 Added 179.3%	857,499 $144 Million
Q4 2017 Feb 13, 2018	BUY	$79.6 - $114.73 $1.2 Million - $1.72 Million	15,015 Added 5.14%	307,020 $30 Million
Q3 2017 Nov 13, 2017	BUY	$66.19 - $103.46 $19.3 Million - $30.2 Million	292,005	292,005 $30.2 Million

Others Institutions Holding BGNE

# of Institutions

216

Shares Held

45.1M

Call Options Held

76.5K

Put Options Held

72.3K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $15.4B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Bei Gene, Ltd. Transaction History